German Medical Advancement Reflects Major Improvement in Individuals with Common and Chronic Illnesses Related to Immune System Dysfunction

German Medical Advancement Reflects Major Improvement in Individuals with Common and Chronic Illnesses Related to Immune System Dysfunction

A new preparation highly beneficial in patients with ailments from common skin disorders to hepatitis or HIV, is now available in the US without a prescription. Oral intake of the GKL03 synthetic peptides induces modulation and regulation of the immune system. GKL03 (Thymrevit) is a demonstrably potent immmunomodulator effective in the short term.

Mannheim, Germany -- A new preparation highly beneficial in patients with ailments from common skin disorders to hepatitis or HIV, is now available in the US without a prescription. Oral intake of the GKL03 synthetic peptides induces modulation and regulation of the immune system. GKL03 (Thymrevit) is a demonstrably potent immmunomodulator effective in the short term.

This preparation was first used in 2004 on tumor patients whose immune system was significantly weakened by chemotherapy or radiotherapy which had been carried out or recently administered. All subjects felt significantly better in several chemotherapy phases each time GKL-03 was taken, and also had better excersise tolerance in endurance test. Since 2004, ongoing clinical trials conducted in Germany, has shown GKL-03 to be adventageous in those with tumourigenic disease, cancer or immuno deficiencies. There are unambiguous findings indicating GKL-03 can protect the body from opportunistic infections where the body has been damaged from pre-existing conditions such as chemotherapy, x-rays, or bacterial, fungal or latent viral infections. "Since such a short term improvement of immune disorders is extremely difficult to achieve, I venture to assume with all reserve a positive effect of the GKL-03" --- Dr. Med Knut Briken, Oncology/Immunobiological Cancer Aftercare, Berlin Germany.

Klett-Loch GmbH, a medium size company, located in Mannheim Germany is a top leader in research and development against immune system disorders for over 25 years. Biotechne Complex, Inc. (www.biotechne.com) located in Georgia is designated the North American representative since 1995 assisting in continued support and informational programs.

###

Contact Information Martin Wainright

Biotechne Complex, Inc.

http://www.biotechne.com

800-214-8631

Pixavi Releases Recession Proof Technology

Pixavi Releases Recession Proof Technology

Pixavi today officially launched its new Xcaster series of wireless High Definition video communication products designed and optimized to help companies and organizations achieve considerable cost savings and efficiency improvements. These goals are particularly important in the current world economic climate, where the impact of recession and a global financial crisis is felt everywhere. The product is capable of virtually eliminating the need for travel in several situations, and to considerably improve the way employees interact and perform.

Stavanger, Norway (PRWEB) March 1, 2009 -- Pixavi today launched its new video collaboration product, the Xcaster. The product is expected to provide considerable cost savings and efficiency improvements to small business all the way up to large multinational corporations and organizations.

The Xcaster is a compact, wireless videoconferencing and collaboration camera, capable of communication and collaboration using high definition video and cd quality audio to any computer, video conferencing or telepresence endpoint. The Xcaster can connect from the field to anywhere in the world using a standard internet connection or a satellite link. The Xcaster user is able to connect from the field to experts and coworkers located practically anywhere, in order to solve problems and visually discuss issues and collaborate in real time. Both parties are offered an audiovisual experience so far offered only by stationary and meeting room HD video conference systems. The result is obvious: Reduced travel cost and increased efficiency.

Background:

The new and technically advanced Xcaster is designed to help organizations face today's challenging global situation dominated by issues like a financial crisis, global warming, pollution, terror threats, increasing travel costs and increased efficiency demands. The product incorporates cutting edge technology such as high speed wireless (802.11n), Bluetooth, AVC HD and high definition video conferencing.

Video Conferencing support:

The Xcaster has the capability of connecting to any videoconferencing system, Telepresence system or a standard desktop or laptop computer and instantly start communicating using two way high definition video, cd quality audio and 5 megapixel images. It supports both H.323 and SIP, which are the dominant IP video and audio telecommunication standards in today's market. The product can communicate directly over the internet, also with multiparty support without the need for subscriptions or paid services.

Rugged:

The Xcaster comes in a very compact ergonomic and rugged design. Built in high quality Norwegian aluminum, the product is IP68 rated (waterproof), impact proof and drop proof up to 2 meters on to concrete.

Collaboration:

Using Pixavi's laser collaboration technology, combined with an integrated gyroscopic MEMS sensor, the user is able to collaborate in real time over a HD video and audio session ubiquitously with his or her surroundings. The result is an unique and transparent user experience, further excelled by an intuitive user interface.

Applications:

Potential application areas (http://www.pixavi.com/applications-video-communication.html) for the product includes among others the manufacturing industry, oil&gas, chemical industries, building and construction, telemedicine, surveillance, ship yards, mining, journalism, firefighting, law enforcement and military.

Services:

Pixavi offers the Go Live server solution for improving the manageability and ease of connection between the Xcaster and other systems as well as networked multimedia storage. The next generation, Go Live 2.0 provides a secure, encrypted communication solution based on Web 2.0 technology.

Pixavi CEO, Christian Rokseth explains: "High definition video conferencing is becoming increasingly popular, and almost 50% of the video conferencing endpoints and VC enabled computers are now HD capable. This growing trend perfectly matches our target of developing a HD collaboration camera when we started this project."

Mr. Rokseth continues: "This is a communication concept known to both save cost and increase efficiency already proven worldwide by the popular previous generations VisiWear video collaboration products initially introduced by Pixavi back in 1999. Today, many more companies have the Infrastructure in place to start using this technology. Meeting rooms are equipped with video conferencing systems, workers are using high performance laptop computers and wireless networks are therefore becoming a standard. In addition, the Internet has become increasingly suitable for high definition video communication, with increased quality of service, bandwidth and lower latency. In sum this means close to instant access to this technology without considerable investments. Pixavi provides our customers with a complete wireless video collaboration solution (http://www.pixavi.com/systems-pixavi-standard.html), including wireless network solutions (http://www.pixavi.com/networks-wireless.html), wireless surveillance products (http://www.pixavi.com/systems-wireless-cctv.html) and wireless location systems (http://www.pixavi.com/systems-wlan-location.html). With this complete offering, our customers can now deploy a cost efficient, secure and industrial grade communication infrastructure solution all provided from one vendor."

Green Technology:

Pixavi Sales Manager, Thomas Zaubi states: "Green technology is becoming an increasingly important, if not mandatory key to success for maintaining the planet we live on. The Xcaster product has the capability of contributing to a lower carbon footprint for businesses through decreasing the need for travel and improving operational efficiency. We launched the Green Ring of Excellence (http://www.pixavi.com/greenring.html) initiative in an effort to put emphasis on this very important aspect."

Interoperability:

Pixavi has successfully tested interoperability with HD endpoints from leading vendors like Tandberg, Polycom, Lifesize and Radvision.

Pricing & Availability:

The Xcaster ST5000 (http://www.pixavi.com/hardware-xcaster-specifications.html) will be available in May 2009, with a price tag of 7950 USD. In addition, Pixavi is offering 3 levels of service, depending on the customer needs, including hosted and managed services like Go Live 2.0, SIP services and hosted video conferencing software solutions.

Pixavi will shortly be introducing an EX Zone 1 intrinsically safe and explosion proof version of the product.

About Pixavi:

Pixavi is a privately owned Norwegian company offering innovative and industrial grade wireless communication products, including wearable and mobile High Definition video products, wireless network products (802.11n, 802.11g WiFi and WIMAX), WLAN antenna products, location tracking and wireless video surveillance technology.

Pixavi introduced its first video collaboration system back in 1999 (ST1000). The company's award-winning products are used by leading enterprises in a multitude of industries. With a broad suite of high tech open, standards-based (Linux) products, Pixavi has a high focus on technology innovation. Pixavi is currently recruiting and are also looking for potential investors and partners in order to further accelerate growth.

Contact us for more information:

Thomas Zaubi

Sales Director

USA: "+1 408 627 7811"

Norway: "+47 90943156"

sales(a)pixavi (dot) com

www.pixavi.com

Legal notice (http://www.pixavi.com/press_release_legal.html)

# # #

Contact Information Thomas Zaubi

Pixavi

http://www.pixavi.com

+47 90943156

MakroCare opens new office in Tokyo

MakroCare opens new office in Tokyo

MakroCare, a global clinical services firm, opens office in Tokyo.

(PRWEB) March 1, 2009 -- MakroCare, US based multidisciplinary knowledge and technology driven global clinical services firm, which provides clinical research support services to pharmaceutical, biotechnology, and medical device industries has opened its new international office in Tokyo, Japan.

To meet the growing needs and serve its clients in Japan, MakroCare has chosen Tokyo as it's strategic base in Japan. MakroCare has other offices currently in USA (New Jersey, Illinois, Pennsylvania), Asia (India), and Europe (Frankfurt).

About MakroCare:

MakroCare, a global clinical services firm, provides clinical research support to pharmaceutical, biotechnology, and medical device industries. The company offers site selection, patient recruitment, project and data management, clinical monitoring, quality assurance, medical writing, PMS/PharmacoVigilance, biometrics, and regulatory assistance. MakroCare has offices in USA (New Jersey, Illinois, and Pennsylvania), India (New Delhi, Mumbai, and Hyderabad), Japan (Tokyo), and Europe (Frankfurt).

###

Contact Information Shah Javid

MakroCare

http://www.makrocare.com

0019734814834

Naturejobs and CheckOrphan Unite for Rare Disease Day

Naturejobs and CheckOrphan Unite for Rare Disease Day

Naturejobs and CheckOrphan, the leading source for the latest news about rare, orphan and neglected diseases, are proud to announce a new partnership for Rare Disease Day. CheckOrphan will feature a feed of relevant job vacancies and content from naturejobs.com. Jobs will focus on the rapidly emerging fields of rare diseases and personalized medicine. The partnership is another step in CheckOrphan's quest to become a comprehensive platform for rare, orphan and neglected diseases.

Basel, Switzerland (PRWEB) February 28, 2009 -- In support of Rare Disease Day, Naturejobs and CheckOrphan, the leading source for the latest news about rare, orphan and neglected diseases, are proud to announce a new partnership. CheckOrphan will feature a feed of relevant job vacancies and content from naturejobs.com, the leading scientific jobs website. Vacancies will focus on the rapidly emerging fields of rare diseases and personalized medicine.

"Naturejobs.com builds upon the excellent brand of Nature that the research world associates with scientific excellence," notes Ian Sowers, Head of Marketing and PR for CheckOrphan. "We are glad to have Naturejobs as a partner and look forward to equaling their dedication to science and research."

The Job Market, powered by Naturejobs is another step towards achieving CheckOrphan's goal of offering its users a comprehensive platform about rare diseases.

"Now scientists in the fields of rare diseases and personalized medicine can enjoy free and convenient access on www.checkorphan.org to relevant jobs from the naturejobs.com global database of science jobs," says Dan Churchward, European Manager for Naturejobs. "Naturejobs' free online job-posting service offers research institutions and companies an excellent opportunity to attract the cream of scientific talent worldwide."

Vacancies from the naturejobs.com database featured on CheckOrphan will direct visitors to positions within academia or industry in fields such as: research, development, clinical studies, regulatory affairs, marketing, IT, and communications.

"A partner like Naturejobs is great for CheckOrphan," adds David Galipeau, Board Member of CheckOrphan. "We are certain the list of future partners and sponsors will continue to grow, because our door is always open to new ideas and features for CheckOrphan."

"This partnership is representative of Naturejobs' continuing drive to develop innovative solutions to the evolving challenges of scientific recruitment," says Dean Sanderson, Head of Global Advertising, Sales and Sponsorship, Nature Publishing Group. "We are delighted to be collaborating with CheckOrphan to help jobseekers and recruiters in the emerging fields of rare, orphan and neglected diseases."

The Job Market, powered by Naturejobs, also compliments CheckOrphan vision of augmenting the amount of global research into rare, orphan and neglected diseases.

"Without research you do not obtain innovative solutions, and without innovation you cannot create a cure for a rare disease," notes Tatsuo Satoh, Managing Director of CheckOrphan. "Research is a strong emphasis of CheckOrphan and we will always be dedicated to furthering research efforts with rare diseases."

CheckOrphan is home to a database of over 6,800 rare diseases and a database of over 8,000 news articles. It also aggregates the latest research news articles and press releases from universities and academic institutes. Users can also consult and contribute to a database of researchers around the world who are working on improving our scientific knowledge of rare diseases.

About Naturejobs

Naturejobs is the largest dedicated job board for the scientific community with over 5,000 job posts advertised globally on the website. Job postings to the website are free and employers using the site range from top pharmaceutical and biotechnology companies to highly respected academic and government institutions. Naturejobs.com is free to use for jobseekers, attracting mores than 2.5 million page views per month. Naturejobs is the careers and recruitment section for Nature Publishing Group, publishers of Nature. For more information, visit www.naturejobs.com

About CheckOrphan

CheckOrphan is the leading source for news and information about rare diseases. Its news database holds the largest concentration of articles about rare diseases, with over 8,000 entries. In addition, CheckOrphan's users benefit from several other large databases that include: the latest research publications, clinical trials, products in development or currently on the market for rare, orphan and neglected diseases, videos, hospitals, researchers and more. It is also home to iWish - without a wish, there is no hope for a better tomorrow. CheckOrphan is always interested in meeting new partners and supporters. CheckOrphan is non-profit organization and encourages its visitors to submit content and information to the platform. CheckOrphan would like to thank the Gebert-Rüf Stiftung for its support. Please visit http://www.grstiftung.ch/_english/index.html for more information about this foundation.

About Halosys

Halosys is a company that transforms real life scenarios in Online and Mobile Solutions by offering a unique blend of Creativity, Knowledge and Technology. Halosys is a New Media Technology Services Company that helps its clients create innovative Online and Mobile solutions. Our efforts on the Web are focused on developing innovative and engaging applications that are new in the market or something we believe can bring Return on Investment to our clients. We develop world class quality web 2.0 sites and applications by considering the latest development trends and techniques with a special emphasis on community creation. On Mobile front, we are among the industry front runners and are among the first to develop applications for some of the platforms, including iPhone.

Contacts:

Naturejobs

Dan Churchward

European Manager

Tel: +44 20 7843 4966

E-mail: d.churchward (at) nature (dot) com

Web: http://www.naturejobs.com

CheckOrphan

Ian Sowers

Head of Marketing and PR

Tel: +41 61 267 0447

E-mail: ian.sowers (at) checkorphan (dot) org

# # #

Contact Information Rober Derham

CheckOrphan

http://www.checkorphan.org

41612670447

CheckOrphan Launches iWish to Commemorate Rare Disease Day

CheckOrphan Launches iWish to Commemorate Rare Disease Day

CheckOrphan, the leading news site for rare, orphan and neglected diseases, launches iWish, which allows people to visually (creative, artistic and realistic images) show their conception of these diseases through and image. In addition, people are invited to explain their imagery and add their iWish - which should convey creative solutions for a rare disease or for the community in general.

Basel, Switzerland (PRWEB) February 28, 2009 -- Today, CheckOrphan is launching one of its flagship features - iWish (http://www.checkorphan.org/content/iWish) - in conjunction with Rare Disease Day, February 28, which is an international effort to raise awareness for rare diseases and the needs of people affected by them.

To help commemorate this day, iWish is a way for people affected by, or working with, rare diseases to step forward and tell their stories through words and images. Currently, CheckOrphan is accepting iWish submissions in English, Spanish, French, German, and Italian.

Participants are asked to provide a text of up to 1,000 words describing a change or development they would like to see in the world of rare diseases - their iWish. They are also encouraged to discuss their experience with a rare disease or diseases, if applicable, and to provide and describe an image (a photograph or other creative image) that in some way complements or illustrates their text. Examples of some iWish contributions can be viewed at:

http://www.checkorphan.org/content/iWish

"People affected by a rare disease have the chance to show the world in an artistic or realistic way through a picture and words what it is like to have a rare disease," explains Ian Sowers, Head of Marketing and PR for CheckOrphan. "But, we also encourage industry professionals, physicians, researchers and others to explain want they encounter as well. This way the world will have a complete view of the problem, accompanied with ways to overcome the hurdles that rare, orphan and neglected diseases face."

CheckOrphan's goal is to allow people around the world to provide creative solutions, through their iWish. At the same time CheckOrphan offers people the opportunity to make an iWish come true. People who want to support an iWish can contact CheckOrphan and then CheckOrphan will contact the individual who submitted the iWish on behalf of the interested supporter.

"Rare, orphan and neglected disease need solutions. They are a huge drain on families and society in general," says Robert Derham, President of CheckOrphan. "So as the saying goes 'two heads are better than one' - we believe that 7 billion heads will be even better. Collectively we will be able to think outside of the box and start to bring solutions to the hundreds of millions of people that are affected with rare, orphan and neglected diseases."

Since its inception two years ago, CheckOrphan.org has become the leading online source of news about rare, orphan, and neglected diseases.

Recently re-launched with a new look and increased functionality, CheckOrphan is dedicated to being a complete web platform for rare diseases that unites and empowers researchers, physicians, professionals and, most importantly, those affected by rare diseases so that they can initiate change.

CheckOrphan's features include: a database of over 8,000 news articles (http://www.checkorphan.org/news) about rare diseases, events, clinical trials, treatments (http://www.checkorphan.org/node/8379), research publications, physician-researcher-hospital-organization-industry databases, videos, daily newsletters and more. Users can submit content for each feature

About CheckOrphan

CheckOrphan is the leading source of news about rare, orphan and neglected diseases. Its news database holds the largest concentration of articles about rare diseases, with over 8,000 entries. CheckOrphan's users benefit from several large databases that also include: events, treatments, research publications, physician-researcher-hospital-organization-industry databases, videos, daily newsletters and more. It is also home to iWish - every wish means hope for a better tomorrow.

CheckOrphan is a non-profit organization that encourages its visitors to submit content and information to the platform. CheckOrphan is always interested in meeting new partners and supporters. CheckOrphan would like to thank the Gebert Rüf Stiftung for its support. For more information about this foundation, please visit http://www.grstiftung.ch.

Contact:

CheckOrphan

Ian Sowers

Head of Marketing and PR

Tel: +41 61 267 0447

Mob: +41 79 719 5539

Robert Derham

President

Tel: +41 61 267 0447

Mob: +41 78 662 5231

###

Contact Information Robert Derham

CheckOrphan

http://www.checkorphan.org

+41 61 267 0447

Ian Sowers

CheckOrphan

http://www.checkorphan.org

Inspired Cancer Survivor Launches Customized Hair Replacement Techniques at Award-Winning Hair Salon

Inspired Cancer Survivor Launches Customized Hair Replacement Techniques at Award-Winning Hair Salon

Greenbelt, MD Salon & Hair Replacement Center, Hair Fantasy, LLC is now offering new innovative hair replacement services for clients battling with hair loss, thinning hair or baldness.

Greenbelt, MD (PRWEB) February 27, 2009 -- There are several reasons for hair loss that may be attributed to chemotherapy from cancer, burn trauma, alopecia, male pattern baldness, follicular damage, side effects from medication, iron or zinc deficiency and/or the effects associated with aging.

As a former cancer survivor, the Owner and Executive Stylist at Hair Fantasy, LLC, Anita Hampton, says that "she is aware of the circumstances surrounding hair loss, due to her own experience with chemotherapy. She totally empathizes with this struggle and understands the impact that hair loss can have on one's self-esteem". Anita Hampton's passion was sparked in her effort to help others look and feel good about their hair and themselves.

Ms. Hampton discovered that wearing a wig does not lend itself to the natural flexibility of life nor does a wig mimic a real head of hair. Hair Fantasy's newly launched Hair Replacement (www.hairfantasy.net) solution offers hair that one can swim in, exercise in, style, sleep in, shower in--and hair that is so uniquely customized that it resembles one's own natural hair!

At Hair Fantasy, miracles have been created by the formation of undetectable hair replacement units. The staff at Hair Fantasy understands that hair loss and hair replacement are personal, sensitive and private matters and therefore ensures that each client receives a private consultation. The complete hair replacement process is also done in private. All hair units are made with 100% human hair and come in a variety of textures, colors and lengths. The hair unit, which does not consist of tracks, is custom made and custom fitted to each client's head.

About Hair Fantasy, LLC

Hair Fantasy (www.hairfantasy.net)'s goal and mission is to turn hair loss trauma into hair replacement triumph, while serving clients with dignity and respect. Hair Fantasy, LLC has been a longstanding participant and sponsor for various events within the American Cancer Society and Susan G. Komen for the Cure Foundation. Hair Fantasy, LLC is also a member of the National Cosmetology Association and the proud recipient of the Prince George's County Small Business Initiative's "Outstanding Retail" of the Year Award for highlighted business accomplishments and commitments to the community.

CONTACT INFORMATION

Anita Hampton

Hair Fantasy, LLC

(301)806-HAIR (4247)

www.hairfantasy.net

###

Contact Information Anita Hampton

Hair Fantasy, LLC

http://www.hairfantasy.net

(301)806-4247

Stemedica Medical Team Cautions Patients About Stem Cell Therapy & Comments on PLoS Medicine Article

Stemedica Medical Team Cautions Patients About Stem Cell Therapy & Comments on PLoS Medicine Article

Stemedica provides its observations and comments to the media regarding the PLoS Medicine article published online February 17, 2009. The PLoS Medicine article describes a patient who developed "brain tumors" (glioneuronal neoplasms) after undergoing repeated transplants of "fetal neural stem cells" in Russia starting in 2001.

San Diego, California (PRWEB) February 27, 2009 -- Stemedica Cell Technologies (http://www.stemedica.com), Inc. ("Stemedica") provided its observations and comments to the media regarding the PLoS Medicine article published online February 17, 2009. The PLoS Medicine article describes a patient who developed "brain tumors" (glioneuronal neoplasms) after undergoing repeated transplants of "fetal neural stem cells" in Russia starting in 2001.

"All of us at Stemedica would like to extend our condolences to the young patient involved in this situation and our hope is for a speedy and positive outcome to this unfortunate experience. Never before have we or any of our Principal Investigators ever encountered such an occurrence either in our own research or in any of the published research", said Dr. David Howe, Stemedica's Vice President and Medical Director.

"We want to use this unfortunate incident to warn those seeking stem cell therapy abroad," warns Dr. Nikolai Tankovich, President & Chief Medical Officer of Stemedica, "to make certain that the manufacturer of the stem cells used in transplantation comply with the rigid standards that have been established by the FDA and other Internationally-recognized regulatory agencies. The future of this industry and the safety of all future patients depend on such adherence." FDA Compliance and Surveillance Standards can be referenced by visiting www.fda.gov/cber/compliance.htm (http://www.fda.gov/cber/compliance.htm).

The report in PLoS, Donor-Derived Brain Tumor Following Neural Stem Cell Transplantation in an Ataxia Telangiectasia Patient (http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.1000029), describes the development of multifocal glioneuronal neoplasms along the spinal nerves and brain stem in a 13-year-old patient who underwent repeated transplantation procedures in an attempt to treat ataxia-telangiectasia (A-T). A-T is a progressive neurodegenerative disorder known to have an increased risk of developing cancer.

Malignancy and neoplasia are common in A-T secondary to deficient cellular and humoral immunity. This immune deficiency is a contra-indication to stem cell transplant therapy. In addition, the mutations associated with A-T in the A-T mutation gene lead to mutations in nuclear protein, which normally repairs DNA. This loss of DNA repair combined with immune deficiency in A-T increases risk of neoplasia with and without cellular transplant therapy in A-T.

"Due to age, children and adolescents have significantly increased quantities of growth factors. Adding stem cells, known for their growth factor production capabilities, to a child with this presenting condition may have been a contributing factor. As in the administration of pharmaceuticals, many of which are not recommended for use in children and adolescents in the same way as in treating adults, great care must be taken in using stem cell therapy with this population of patients", said Dr. Michael Bayer, Stemedica's Director of Medical Services.

Based on the facts and references cited within the PLoS Medicine article, researchers have discovered that some of the cells were female and had two copies of the gene that causes A-T. Karyotype testing was reported in this case which confirms inadequate testing of the stem cells prior to transplantation. "The stem cell preparation protocol provided to the parents by the treatment team was reviewed and found to be inadequate by our standards", said Dr. Howe. "No cell characteristics, cell markers or bio-safety data was present. Mechanical desegregation in the 8-12 week age fetus is not recommended. Enzymatic separation is preferred, a process that also removes any dead cells that may be present. There is also a significant lack of detail on the number of cell passages as well as the dispersion of the neurospheres", Dr. Howe went on to say.

Dr. Alex Kharazi, Stemedica's Vice President for Manufacturing & Research observed, "Limited cell culturing in only 12-16 days as described in their protocol is like using a crude primary culture of cells. There are numerous risks associated with using crude cell preparations that have not been subjected to rigid manufacturing and testing protocols such as purity, identity and potency. In addition, the antibiotics used to manufacture the stem cells, are potentially neurotoxic." Dr. Kharazi went on to say, "Overall the description provided for the manufacturing protocol was vague and a poor example of what a well thought out manufacturing and safety-driven process should be. For example, there was no data provided relating to tumorgenicity, toxicity, or bio-distribution testing of the manufactured cells in nude mice which is a mandatory requirement as a first and critical step to assessing cell safety."

"Stemedica is committed to a manufacturing process that puts safety first at all times. Our stem cell product lines go through extensive testing during several stages of the manufacturing process and are also subjected to in-depth pre-clinical studies before filing with the FDA and other regulatory agencies for clinical trials", continued Dr. Kharazi. "Nothing is more important than the welfare of the patient and there is no explanation that can justify any deviance from compliance to FDA guidelines for the manufacturing and testing of stem cells prior to administration. These are the guidelines we follow and any patient considering stem cell therapy, at any location worldwide, should confirm that the manufacturer is in full compliance before they decide to undergo stem cell transplantation." warns Dr. Kharazi.

About Stemedica Technologies, Inc.

Stemedica Cell Technologies Inc. (http://www.stemedica.com (http://www.stemedica.com)) is a specialty biopharmaceutical company that is committed to the development and manufacture of best-in-class adult stem cells for use by approved research institutions and hospitals for pre-clinical and clinical studies. Stemdedica complies with the standards and guidelines established by the FDA and the FDB (Food and Drug Board) in the manufacturing and testing of its stem cells. Within the United States, the Company is currently developing regulatory pathways for stroke, traumatic brain injury and wound repair. Outside the United States, Stemedica provides its adult stem cells to hospitals and research centers that are conducting studies under protocols approved by the appropriate regulatory agencies. These studies are focused on the treatment of neurodegenerative diseases, sight restoration and wound repair. Stemedica is based in San Diego, California.

Media Contact for Stemedica: Dave McGuigan at dmcguigan (at) stemedica.com.

###

Contact Information Dave McGuigan

Stemedica Cell Technologies Inc

http://www.stemedica.com

+1 858 658 0910